Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
Phuc Le(Cleveland Clinic), Michael B. Rothberg(Cleveland Clinic), Glen B. Taksler(Cleveland Clinic), Naim Alkhouri(Ohio Aerospace Institute), William H. Herman(University of Michigan), Olajide A. Adekunle(Cleveland Clinic), Moosa Tatar(University of Houston), Arthur J. McCullough(Cleveland Clinic), Srinivasan Dasarathy(Cleveland Clinic), Wen Ye(University of Michigan), Abhishek Deshpande(Cleveland Clinic)
Cited by 177
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
|Diabetes Care|2016|969
Public Reporting and Pay for Performance in Hospital Quality Improvement
|New England Journal of Medicine|2007|853